IQVIA CEO Says He Believes It Won Big In Pharma Contract Reshuffle, While Smaller Rivals 'Lost Out'
Ari Bousbib said large drugmakers reopened their outsourcing deals, and he expects the damage to smaller research firms to show within two or three years.
IQVIA Chairman and CEO Ari Bousbib said on the company's third-quarter earnings call Tuesday that he believes IQVIA "emerged more ahead than the others" when big pharma reopened its strategic partnerships, and that he thinks smaller research firms "lost out overall." IQVIA, which runs clinical trials and sells healthcare data and analytics to drugmakers, reported trailing-12-month net new bookings of $11.7 billion, up 14% from a year earlier.
Three tiers after the renegotiations
Answering a Jefferies analyst, Bousbib said every large pharma company renegotiated its strategic partnerships, a process that lasted a year, maybe a year and a half, and ended not long ago. IQVIA came out with more partnerships and a broader scope within them, he said.
He said the process split the contract research industry into three groups: the largest firms, the small-to-mid players, and "a long tail of little players." He credited IQVIA's broad capabilities and AI, and pointed to win rates that have kept ticking up two to three points.
Of the smaller tier, Bousbib said "I think" they lost out, and that it "is going to become apparent over the next two or three years." His reasoning: "we know who's out, and they're all out, basically." That is his own view of the industry, not a reported outcome.
Why pharma paused
Bousbib described two to three years of headwinds: a post-COVID slowdown, drug-pricing worries tied to the Inflation Reduction Act, most-favored-nation pricing and tariffs. That uncertainty made large pharma pause decisions and stretch timelines, he said.
He also said that earlier this year analysts feared full-service outsourcing was over. He said he had warned that the pendulum swings and the long-term outsourcing trend is intact; full-service bookings were very strong again this quarter.
The quarter behind the claim
Third-quarter revenue was $4.428 billion, up 8% as reported and 8.6% at constant currency. Adjusted diluted earnings per share rose 11.3% to $3.34. Research and development solutions booked $3.2 billion of net new bookings, up 15% from a year earlier, a book-to-bill ratio of 1.2.
Management raised full-year 2026 guidance for revenue, adjusted EBITDA and adjusted diluted EPS. Revenue is now expected at $17.35 billion to $17.5 billion, and adjusted EPS at $12.90 to $13.00. IQVIA's market value was $45.0 billion in Tuesday morning trading.
IQVIA holds an investor day on December 1, where it will outline a broad 2027 framework, with detailed guidance due alongside fourth-quarter results in February 2027.
Sources
- IQVIA Hldgs Q3 2026 Earnings Call Transcript — benzinga.com
- IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates — Yahoo Finance
- IQVIA Non-GAAP EPS of $3.34 beats by $0.06, revenue of $4.43B beats by $60M (IQV:NYSE) | Seeking Alpha — seekingalpha.com
- IQVIA stock gains as R&D Solutions drive Q3 beat (IQV:NYSE) | Seeking Alpha — seekingalpha.com
- IQVIA Holdings Inc. (IQV) Stock Price, News, Quote & History — Yahoo Finance